key: cord-0700024-31urk6xn
authors: Badagliacca, Roberto; Sciomer, Susanna; Petrosillo, Nicola
title: Endothelin receptor antagonists for pulmonary arterial hypertension and COVID-19: friend or foe ?
date: 2020-04-17
journal: J Heart Lung Transplant
DOI: 10.1016/j.healun.2020.04.007
sha: f9164b23f6353a2e3c4c7380280ab9bdc20d2875
doc_id: 700024
cord_uid: 31urk6xn

nan

CoronaVirus Disease-19 (COVID-19) poses a threat to individuals with chronic health conditions who are more likely to develop severe pneumonia and death. Those with pulmonary arterial hypertension represent such a high-risk group. Severe COVID-19 presents with respiratory failure secondary to immuno-pathologic injury likely due to a combination of direct cytopathic effects of the virus in concert with an aberrant immune response. The interplay between these two components has been recently better understood. Indeed, the SARS-CoV-2 genome encodes eight accessory proteins designated open reading frame (ORF) with identified functions. In particular, the ORF-3a protein initiates necroptosis once oligomerized by Rip-3, allowing it to form a potassium-sensitive channel inserted into late endosomal, lysosomal, and trans-Golgi-network membranes (1). Rip3-driven oligomerization of ORF-3a plays a critical role in driving necrotic cell death, independent from and hijacking Rip3-MLKL necroptotic signaling. There is considerable evidence that an abundance of necroptosis perpetuates pathogenic inflammation and drives tissue injury (2) . Fatal cases of SARS-CoV-2 infection similarly show significant lung damage in response to inflammation, which may very well be driven by necroptosis (3). Endothelin-1 (ET-1) effects on cell survival and death may vary depending on cell type, concentrations and disease conditions. In contrast to low-physiological doses, high levels of ET-1 usually trigger activation of necroptotic gene expression (4) . For this reason pulmonary arterial hypertension patients may be prone to activate the necroptotic pathways.

Furthermore, under inflammatory and endotoxemic stress conditions, as in severe acute respiratory syndromes, ET-1 mediated effects are shifted to promote necroptosis through a potent and long lasting RIP-3 activation (4,5), thereby enhancing oligomerization of the ORF-3a protein and increasing the catastrophic effects of the proinflammatory necroptotic cell death to SARS-CoV-2 pathogenesis. Blocking of ET receptors with Bosentan is able to inhibit the necroptosis pathway in experimental models of microvascular endothelial cells (5) . As endothelin receptor antagonists counteract the vicious circle of ET-1-mediated RIP-3 activation and propagation of the proinflammatory necroptotic cell death, as it happens in the worst form of SARS, we propose that it seems safe to continue endothelin receptor antagonists in patients on treatment with this class of drugs.

SARS-Coronavirus Open Reading Frame-3a drives multimodal necrotic cell death

RIP3: a molecular switch for necrosis and inflammation

Lung pathology of severe acute respiratory syndrome (SARS): a study of 8 autopsy cases from Singapore

Many stimuli pull the necrotic trigger, an overview

SARS-Coronavirus Open Reading Frame-3a drives multimodal necrotic cell death

None.

R Badagliacca has received fees as speaker and scientific consultant for GSK, UT, Dompè, Ferrer, Bayer, MSD, AOPOrphan Pharmaceuticals. S. Sciomer and N. Petrosillo have nothing to disclose.